For the Inventor, By the Inventor

Enter assignee name

Grand Cayman, Cayman Islands

Beigene, Ltd.

USPTO Granted Patents = 52

CIPO Patents = 16

EPO Patents = 18

Trademarks = 20

Forward Citations = 650

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Changyou Zhou (25 out of 44 patents)

Zhiwei Wang (18 out of 63 patents)

Hexiang Wang (14 out of 15 patents)

4. Guoliang Zhang (14 out of 17 patents)

5. Yunhang Guo (12 out of 23 patents)

6. Bo Ren (12 out of 13 patents)

7. Kang Li (11 out of 32 patents)

8. Tong Zhang (10 out of 87 patents)

9. Jing Li (7 out of 132 patents)

10. Jing Song (7 out of 15 patents)

11. Qi Liu (5 out of 100 patents)

12. Min Wei (4 out of 14 patents)

13. Haibo Zhao (4 out of 4 patents)

14. Hao Peng (4 out of 11 patents)

15. Geoffrey Kim (3 out of 3 patents)

Core Competencies:

Cyclic Dinucleotides

Bcl-2 Inhibitors

TLR7 Agonists

HPK1 Inhibitors

Anti-OX40 Antibodies

Immunotherapy

A2A Receptor Antagonists

BTK Inhibitors

PARP Inhibitors

Anti-PD-L1 Antibodies

Raf Kinase Inhibitors

Indoleamine 2,3-Dioxygenases

52 patents: Sort by Forward Citations

1. 12435104 - Cyclic dinucleotides as sting agonists (2025-10-07),

2. 12286430 - Bcl-2 inhibitor (2025-04-29),

3. 12281119 - Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist (2025-04-21),

4. 12195449 - 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof (2025-01-14),

5. 12103974 - Anti-OX40 antibodies and methods of use (2024-10-01),

6. 12077536 - BCL-2 inhibitors (2024-09-03),

7. 11905294 - Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors (2024-02-20),

8. 11875885 - Interoperable platform for reducing redundancy in medical database management (2024-01-16),

9. 11725012 - Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors (2023-08-15),

10. 11636930 - Interoperable platform for reducing redundancy in medical database management (2023-04-25),

11. 11597768 - Immunotherapy for hepatocellular carcinoma (2023-03-07),

12. 11555038 - Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-01-17),

13. 11512132 - Anti-PD-L1 antibodies and their use as therapeutics and diagnostics (2022-11-29),

14. 11472811 - Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist (2022-10-18),

15. 11472788 - Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases (2022-10-18),

BeiGene, Ltd. is a commercial-stage biotechnology company that focuses on developing and commercializing innovative medicines for cancer treatment. With a global presence, BeiGene combines cutting-edge science and technology to discover, develop, and deliver globally accessible oncology drugs. The company is committed to improving treatment outcomes and patient lives through its pipeline of targeted and immuno-oncology therapeutics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

52 Patents

#23 in Grand Cayman

#28 in Cayman Islands

#13,143 in the World

Grand Cayman, Cayman Islands

Beigene, Ltd.

Forward Citations = 650

48 inventors:

Changyou Zhou (25 out of 44 patents)

Zhiwei Wang (18 out of 63 patents)

Hexiang Wang (14 out of 15 patents)

4. Guoliang Zhang (14 out of 17 patents)

5. Yunhang Guo (12 out of 23 patents)

Please report any incorrect information to support@idiyas.com

Loading…